Also known as: 1-Bromo-1-(bromomethyl)-1,3-propanedicarbonitrile, MDBGN, Caswell No. 114G, EINECS 252-681-0, EPA Pesticide Chemical Code 111001 (+4 more)
CAS 35691-65-7
1,2-Dibromo-2,4-dicyanobutane (CAS 35691-65-7) is a chemical substance with GHS signal word Danger; key hazard signal: H330; H302; H373 (thyroid, central nervous system); H318; H317; H411. Key regulatory status: 16 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from ECHA CLP, EPA ToxValDB, EPA CPDat, AICIS, SCCS, ILO ICSC, EPA TRI.
View cosmetic safety profile for Methyldibromo Glutaronitrile →
1,2-Dibromo-2,4-dicyanobutane is prohibited in EU cosmetics but has active industrial GHS classifications (H330, H302, H373, H318, H317, H411).
CAS, identifiers, formula, and alternate names for the matched substance record.
EU harmonized hazard classification, hazard statements, pictograms, and signal word.
| Hazard Class | H-Statements | Pictograms | Signal |
|---|---|---|---|
| Acute Tox. 2; Acute Tox. 4; STOT RE 2; Eye Dam. 1; Skin Sens. 1A; Aquatic Chronic 2 | H330; H302; H373 (thyroid, central nervous system); H318; H317; H411 | GHS06; GHS08; GHS05; GHS09 | Danger |
International Chemical Safety Card hazard and exposure summary.
| Field | Value |
|---|---|
| Short-term Effects | The substance is irritating to the eyes and skin. |
| Long-term Effects | Repeated or prolonged contact may cause skin sensitization. |
| Routes of Exposure | The substance can be absorbed into the body by ingestion. |
Industrial and product-use categories associated with this substance.
Inventory, screening, and regulatory list matches from public chemical databases.
| List | Keyword | Source |
|---|---|---|
| CEDI | FDA | United States Food and Drug Administration (FDA) |
| Indirect additives food contact (10/2018) | FDA | United States Food and Drug Administration (FDA) |
| inert_ingredient; non_food_use; Pesticides | EPA | CPCat |
| active_ingredient; Europe; Pesticides | Commission of the European Communities | CPCat |
| Canada; pharmaceutical | DrugBank | DrugBank |
| Canada; pharmaceutical | DrugBank | DrugBank |
| consumer_product; Europe | Danish Environmental Protection Agency | Danish EPA |
| Europe; Personal care - body hygiene - hand soap | Danish Environmental Protection Agency | Danish EPA |
| active_ingredient; Pesticides | State of California | State of California |
| active_ingredient; Pesticides | State of California | State of California |
| active_ingredient; Pesticides | State of California | State of California |
| active_ingredient; Pesticides | State of California | State of California |
| active_ingredient; Pesticides | State of California | State of California |
| active_ingredient; Pesticides | State of California | State of California |
| active_ingredient; Pesticides | State of California | State of California |
| active_ingredient; Pesticides | California Department of Pesticide Regulation | State of California |
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 35.93 | uM | AC50 | - | - | NTP ICE endocrine |
| 33.79 | uM | ACC | - | - | NTP ICE endocrine |
| 2.9 | ug/mL | CD54, EC200 | Dermal | - | NTP ICE skin sensitization |
| 9.42 | ug/mL | CD54, EC200 | Dermal | - | NTP ICE skin sensitization |
| 9.8 | ug/mL | CD54, EC200 | Dermal | - | NTP ICE skin sensitization |
| 17.7 | ug/mL | CD54, EC200 | Dermal | - | NTP ICE skin sensitization |
| 3.04 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| 6.5 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| 7 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| 8 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| 10 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| 10.8 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| 14 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| >1862 | ug/mL | CD86, EC150 | Dermal | - | NTP ICE skin sensitization |
| 5.67 | ug/mL | CV70 | Dermal | - | NTP ICE skin sensitization |
| 8.6 | ug/mL | CV75 | Dermal | - | NTP ICE skin sensitization |
| 9.4 | ug/mL | CV75 | Dermal | - | NTP ICE skin sensitization |
| 9.9 | ug/mL | CV75 | Dermal | - | NTP ICE skin sensitization |
| 14.4 | ug/mL | CV75 | Dermal | - | NTP ICE skin sensitization |
| 18.7 | ug/mL | CV75 | Dermal | - | NTP ICE skin sensitization |
| 23.3 | ug/mL | CV75 | Dermal | - | NTP ICE skin sensitization |
| 75.3 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 99 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 99.6 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| 100 | % | Depletion Cys | Dermal | - | NTP ICE skin sensitization |
| -576 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 6 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 28.4 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 28.6 | % | Depletion Lys | Dermal | - | NTP ICE skin sensitization |
| 50 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 51.8 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 52.5 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 64.3 | % | Depletion Lys + Cys | Dermal | - | NTP ICE skin sensitization |
| 4.73 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 5.5 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 5.92 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 6.39 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 6.4 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 6.7 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 7.2 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 7.21 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 7.4 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 7.785 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 7.84 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 7.89 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 7.95 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 8 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 8.8 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 10 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
| 10.25 | uM | EC1.5 | Dermal | - | NTP ICE skin sensitization |
Showing 50 of 97 studies
TRI hazard and reporting flags for the matched chemical.
| Chemical | Category | Flags |
|---|---|---|
| 1-Bromo-1-(bromomethyl)-1,3-propanedicarbonitrile | - | - |
Australian industrial chemicals inventory status and applicable conditions.
EU Scientific Committee opinions tied to the matched substance.
| Opinion | Date | Conclusion | Max Conc. | Concerns |
|---|---|---|---|---|
| SCCP/0947/05 | 20 June 2006 | Safe with restrictions — safe in rinse-off products at 0.1%; not safe in leave-on products | 0.1% in rinse-off products | Skin sensitization (potent contact allergen); EU subsequently restricted to rinse-off only then later withdrew from leave-on; high sensitization rate confirmed |
| SCCP/0849/04 | 15 March 2005 | Safe with restrictions — safe in rinse-off products at 0.1%; not safe in leave-on products | 0.1% in rinse-off products | Skin sensitization (potent contact allergen); this opinion established the rinse-off-only restriction later confirmed by SCCP/0947/05 |
| SCCP/0863/05 | 2005-03-15 | In response to the questions asked, the SCCP is of the opinion that: MDBGN was shown to cause elicitation of reactions by repeated open exposures with a rinse-off preparation at the maximum concentration allowed in rinse-off products (0.1%). No safe use-level for MDBGN in cosmetic leave-on or rinse-off products has been established. As no safe use-level for MDBGN in rinse-off products has been established, it is recommended that MDBGN should not be present in any cosmetic products. | 0.1% (max allowed in rinse-off; elicits reactions at this level) | Skin sensitisation (allergic contact dermatitis); elicitation at 0.1% in rinse-off; no safe use-level established for leave-on or rinse-off; recommended that MDBGN should not be present in any cosmetic products. Not yet classified as skin sensitizer (R43) in Annex I to Directive 67/548/EEC. COLIPA n P77. |
| SCCP/1013/06 | 2006-06-20 | In response to the question asked by the European Commission, the SCCP is of the opinion that no safe use-level for methyldibromo glutaronitrile in cosmetic rinse-off products has been established. | - | No safe use-level established for methyldibromo glutaronitrile in rinse-off products; sensitisation. SCCP does not alter its previous opinion. |
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
1,2-Dibromo-2,4-dicyanobutane (CAS 35691-65-7) is classified under EU CLP Annex VI as Acute Tox. 2; Acute Tox. 4; STOT RE 2; Eye Dam. 1; Skin Sens. 1A; Aquatic Chronic 2 with signal word Danger. Hazard statements: H330; H302; H373 (thyroid, central nervous system); H318; H317; H411. Source: EU CLP Annex VI (ECHA).
1,2-Dibromo-2,4-dicyanobutane has 97 NOAEL studies in the database. The lowest reported value is -576 % via Dermal. Source: NTP ICE skin sensitization.
1,2-Dibromo-2,4-dicyanobutane appears on 8 regulatory/inventory lists including CEDI, Indirect additives food contact (10/2018), inert_ingredient; non_food_use; Pesticides, and 5 more. Source: EPA CPDat.
Yes, 1,2-Dibromo-2,4-dicyanobutane is also indexed as a cosmetic ingredient under the name Methyldibromo Glutaronitrile. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from ECHA CLP Annex VI, EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, ILO/WHO ICSC, EPA Toxics Release Inventory, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
1,2-Dibromo-2,4-dicyanobutane is prohibited in EU cosmetics but has active industrial GHS classifications (H330, H302, H373, H318, H317, H411).
1,2-Dibromo-2,4-dicyanobutane also appears in cosmetics, pharmaceutical databases.